Results 1 - 20 of 6,679 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Show only
- Peer-reviewed Journals (6,157)
| Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
|---|---|---|---|
| 1 |
Material Type: Article
|
|
Kinase drug discovery 20 years after imatinib: progress and future directionsNature reviews. Drug discovery, 2021-07, Vol.20 (7), p.551-569 [Peer Reviewed Journal]COPYRIGHT 2021 Nature Publishing Group ;Springer Nature Limited 2021. ;Springer Nature Limited 2021 ;ISSN: 1474-1776 ;EISSN: 1474-1784 ;DOI: 10.1038/s41573-021-00195-4 ;PMID: 34002056Full text available |
| 2 |
Material Type: Article
|
|
Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid LeukemiaBiological and Pharmaceutical Bulletin, 2015/05/01, Vol.38(5), pp.645-654 [Peer Reviewed Journal]2015 The Pharmaceutical Society of Japan ;Copyright Japan Science and Technology Agency 2015 ;ISSN: 0918-6158 ;EISSN: 1347-5215 ;DOI: 10.1248/bpb.b15-00103 ;PMID: 25947908Full text available |
| 3 |
Material Type: Article
|
|
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients TrialJournal of clinical oncology, 2016-07, Vol.34 (20), p.2333-2340 [Peer Reviewed Journal]2016 by American Society of Clinical Oncology. ;2016 by American Society of Clinical Oncology 2016 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2015.64.8899 ;PMID: 27217448Full text available |
| 4 |
Material Type: Article
|
|
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertensionThe European respiratory journal, 2022-12, Vol.60 (6), p.2102356 [Peer Reviewed Journal]Copyright ©The authors 2022. ;Copyright ©The authors 2022. 2022 ;ISSN: 0903-1936 ;EISSN: 1399-3003 ;DOI: 10.1183/13993003.02356-2021 ;PMID: 35680144Full text available |
| 5 |
Material Type: Article
|
|
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID studyHaematologica (Roma), 2016-06, Vol.101 (6), p.717-723 [Peer Reviewed Journal]Copyright© Ferrata Storti Foundation. ;Copyright© Ferrata Storti Foundation 2016 ;ISSN: 0390-6078 ;EISSN: 1592-8721 ;DOI: 10.3324/haematol.2015.139899 ;PMID: 26888022Full text available |
| 6 |
Material Type: Article
|
|
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE TrialJournal of clinical oncology, 2018-01, Vol.36 (3), p.231-237 [Peer Reviewed Journal]2017 by American Society of Clinical Oncology 2017 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2017.74.7162 ;PMID: 29091516Full text available |
| 7 |
Material Type: Article
|
|
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid LeukemiaThe New England journal of medicine, 2017-03, Vol.376 (10), p.917-927 [Peer Reviewed Journal]Copyright © 2017 Massachusetts Medical Society. All rights reserved. ;(c) Massachusetts Medical Society, 2017 info:eu-repo/semantics/openAccess ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1609324 ;PMID: 28273028Full text available |
| 8 |
Material Type: Article
|
|
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trialLeukemia, 2016-05, Vol.30 (5), p.1044-1054 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group May 2016 ;Copyright © 2016 Macmillan Publishers Limited 2016 Macmillan Publishers Limited ;ISSN: 0887-6924 ;EISSN: 1476-5551 ;DOI: 10.1038/leu.2016.5 ;PMID: 26837842Full text available |
| 9 |
Material Type: Article
|
|
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trialLeukemia, 2018-07, Vol.32 (7), p.1657-1669 [Peer Reviewed Journal]Copyright Nature Publishing Group Jul 2018 ;ISSN: 0887-6924 ;EISSN: 1476-5551 ;DOI: 10.1038/s41375-018-0179-9 ;PMID: 29925908Full text available |
| 10 |
Material Type: Article
|
|
In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary DeliveryInternational journal of nanomedicine, 2021-01, Vol.16, p.1221-1229 [Peer Reviewed Journal]2021 Xu et al. ;COPYRIGHT 2021 Dove Medical Press Limited ;2021. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2021 Xu et al. 2021 Xu et al. ;ISSN: 1178-2013 ;ISSN: 1176-9114 ;EISSN: 1178-2013 ;DOI: 10.2147/IJN.S294626 ;PMID: 33628019Full text available |
| 11 |
Material Type: Article
|
|
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid LeukemiaJournal of clinical oncology, 2017-01, Vol.35 (3), p.298-305 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.2016.68.2914 ;PMID: 28095277Full text available |
| 12 |
Material Type: Article
|
|
The tyrosine kinase inhibitor imatinib mesylate suppresses uric acid crystal-induced acute gouty arthritis in micePloS one, 2017-10, Vol.12 (10), p.e0185704 [Peer Reviewed Journal]COPYRIGHT 2017 Public Library of Science ;COPYRIGHT 2017 Public Library of Science ;2017 Reber et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;2017 Reber et al 2017 Reber et al ;ISSN: 1932-6203 ;EISSN: 1932-6203 ;DOI: 10.1371/journal.pone.0185704 ;PMID: 28982129Full text available |
| 13 |
Material Type: Article
|
|
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsLeukemia, 2017-11, Vol.31 (11), p.2398-2406 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Nov 2017 ;Copyright © 2017 The Author(s) 2017 The Author(s) ;ISSN: 0887-6924 ;EISSN: 1476-5551 ;DOI: 10.1038/leu.2017.253 ;PMID: 28804124Full text available |
| 14 |
Material Type: Article
|
|
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemiaLeukemia, 2016-01, Vol.30 (1), p.48-56 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Jan 2016 ;ISSN: 0887-6924 ;ISSN: 1476-5551 ;EISSN: 1476-5551 ;DOI: 10.1038/leu.2015.261 ;PMID: 26416462Full text available |
| 15 |
Material Type: Article
|
|
Immunological off-target effects of imatinibNature reviews. Clinical oncology, 2016-07, Vol.13 (7), p.431-446 [Peer Reviewed Journal]COPYRIGHT 2016 Nature Publishing Group ;COPYRIGHT 2016 Nature Publishing Group ;Copyright Nature Publishing Group Jul 2016 ;Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. 2016. ;ISSN: 1759-4774 ;EISSN: 1759-4782 ;DOI: 10.1038/nrclinonc.2016.41 ;PMID: 27030078 ;CODEN: AJHYE6Full text available |
| 16 |
Material Type: Article
|
|
miR-181a plays the tumor-suppressor role in chronic myeloid leukemia CD34 + cells partially via SERPINE1Cellular and molecular life sciences : CMLS, 2024-12, Vol.81 (1) [Peer Reviewed Journal]The Author(s) 2023 ;ISSN: 1420-682X ;EISSN: 1420-9071 ;DOI: 10.1007/s00018-023-05036-8Digital Resources/Online E-Resources |
| 17 |
Material Type: Article
|
|
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cellsNature medicine, 2017-10, Vol.23 (10), p.1234-1240 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group Oct 2017 ;ISSN: 1078-8956 ;EISSN: 1546-170X ;DOI: 10.1038/nm.4399 ;PMID: 28920959Full text available |
| 18 |
Material Type: Article
|
|
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 studyHaematologica (Roma), 2016-12, Vol.101 (12), p.1544-1552 [Peer Reviewed Journal]Copyright© Ferrata Storti Foundation. ;Copyright© Ferrata Storti Foundation 2016 ;ISSN: 0390-6078 ;EISSN: 1592-8721 ;DOI: 10.3324/haematol.2016.144535 ;PMID: 27515250Full text available |
| 19 |
Material Type: Article
|
|
Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysisClinical therapeutics, 2019-12, Vol.41 (12), p.2558-2570.e7 [Peer Reviewed Journal]2019 Elsevier Inc. ;Copyright © 2019 Elsevier Inc. All rights reserved. ;2019. Elsevier Inc. ;ISSN: 0149-2918 ;EISSN: 1879-114X ;DOI: 10.1016/j.clinthera.2019.10.009 ;PMID: 31812340Full text available |
| 20 |
Material Type: Article
|
|
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemiaLeukemia, 2017-05, Vol.31 (5), p.1108-1116 [Peer Reviewed Journal]COPYRIGHT 2017 Nature Publishing Group ;COPYRIGHT 2017 Nature Publishing Group ;Copyright Nature Publishing Group May 2017 ;Copyright © 2017 The Author(s) 2017 The Author(s) ;ISSN: 0887-6924 ;ISSN: 1476-5551 ;EISSN: 1476-5551 ;DOI: 10.1038/leu.2016.360 ;PMID: 27890936Full text available |
Results 1 - 20 of 6,679 for All Library Resources
Sorted by:
Sorted by:
RelevanceOr hit Enter to replace sort method
- Relevance
- Date-newest
- Date-oldest
- Popularity
- Author
- Title
Personalize your results
Refine Search Results
Expand My Results
Show only
- Peer-reviewed Journals (6,157)
Refine My Results
Creation Date
- Before 2001 (37)
- 2001 To 2006 (1,643)
- 2007 To 2012 (2,465)
- 2013 To 2019 (1,919)
- After 2019 (611)
-
More options
New Records
Resource Type
- Articles (6,641)
- magazinearticle (11)
- Reports (10)
- Web Resources (7)
- Book Chapters (5)
- Thesises (postgraduate) (4)
- Books (1)
-
More options
Subject
- Humans (5,837)
- Science & Technology (5,669)
- Imatinib Mesylate (5,402)
- Life Sciences & Biomedicine (5,400)
- Benzamides (3,927)
- Pyrimidines - Therapeutic Use (2,677)
- Piperazines - Therapeutic Use (2,553)
- Male (2,515)
- Oncology (2,498)
- Female (2,298)
- Antineoplastic Agents - Therapeutic Use (2,171)
- Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy (2,154)
- Imatinib (1,997)
- Middle Aged (1,964)
- Adult (1,728)
- Biological And Medical Sciences (1,634)
- Hematology (1,627)
- Pyrimidines - Pharmacology (1,611)
- Medical Sciences (1,582)
- Piperazines - Pharmacology (1,516)
-
More options
Databases
- MEDLINE (6,277)
- ProQuest Central (3,074)
- Geneva Foundation Free Medical Journals at publisher websites (3,048)
- PubMed Central (2,067)
- DOAJ Directory of Open Access Journals (1,591)
- HighWire Press (Free Journals) (1,554)
- ROAD: Directory of Open Access Scholarly Resources (1,280)
- Nature Free (664)
- Springer Nature OA Free Journals (302)
- Wiley Online Library Open Access (260)
- ProQuest One Psychology (163)
- Free E- Journals (150)
- Public Library of Science (PLoS) Journals Open Access (148)
- IngentaConnect Backfiles (136)
- Journals@Ovid Open Access Journal Collection Rolling (121)
- Freely Accessible Japanese Titles (101)
- Taylor & Francis Open Access (99)
- Medknow Open Access Medical Journals (75)
- SWEPUB Freely available online (61)
- Bioline International (59)
-
More options
Language
Journal Title
- Annals Of Hematology (81)
- Blood (439)
- Cancer Research (109)
- Clinical Cancer Research (171)
- Haematologica (188)
- International Journal Of Hematology (129)
- Journal Of Clinical Oncology (146)
- Leukemia (338)
- Plos One (130)
- The New England Journal Of Medicine (76)
-
More options
|
||||
 |
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY |  |
(84-028) 37 755 057 | Feedback |
| 19 Nguyen Huu Tho St. Dist.7, HCM |  |
thuvien@tdtu.edu.vn | ||